NEJM Evidence Impact Factor

NEJM Evidence launched in January 2022. Its About page says the journal received an inaugural 2025 Journal Impact Factor of 11.6 and ranks 13th of 336 journals in the Medicine, General & Internal category according to the 2026 Journal Citation Reports (Clarivate). JIF calculations require citation history within the JCR system, and journals must complete Clarivate evaluation. NEJM Evidence is also tracked in Scopus-style systems with SJR and h-index-style signals, which is useful context but not a substitute for an official JCR Journal Impact Factor.

For current planning, use the inaugural JIF together with Scopus metrics, NEJM Group pedigree, article-level performance, and your institution's metric policy. There is no year-over-year trend yet, because the 2025 figure is the first official NEJM Evidence JIF and there is no previous one to compare against.

NEJM Evidence is a digital-first clinical journal focused on clinical trials, systematic reviews, and original research in evidence-based medicine. It was launched to address a gap: the original NEJM's limited space relative to the volume of high-quality clinical research being produced.

Key characteristics:

• Publisher: Massachusetts Medical Society (same as NEJM)

• Editorial identity: senior clinical editors within the NEJM Group

• Launch date: January 2022

• Format: Digital-only; no author submission or publication fees, with Author Accepted Manuscript deposit for funder mandates

• Scope: Clinical trials, systematic reviews, meta-analyses, epidemiology studies, first-in-human trials

The practical point is simple: NEJM Evidence now has a JIF, but only one, the inaugural 2025 figure of 11.6 printed on the journal's About page. With no earlier listing there is no trend to read, so treat the number as a starting point rather than a track record.

For authors, this creates a practical consideration:

Some promotion committees and grant applications specifically require a listed JIF. If your institution uses JIF as a formal filter for promotion cases, submitting to NEJM Evidence carries a risk because reviewers may not count a single inaugural listing the same way they would count a journal with a longer JIF record.

If your institution is more flexible about journal quality vs. listed metrics, NEJM Evidence's pedigree and editorial standards should carry weight equivalent to other high-quality clinical journals.

Alongside the JIF, NEJM Evidence is tracked by other indexing services. Here's what's available.

The Scopus SJR of 1.154 and Q1 quartile confirm that citation databases are tracking the journal and that its early citation performance is strong. For committees that accept Scopus metrics alongside or instead of JCR, this data point can help.

For manuscripts targeting NEJM Evidence, three failure patterns account for most of the issues we identify before submission.

Submitting without confirming institutional metric policy.

The single most consequential issue we see is researchers submitting to NEJM Evidence without first verifying whether their institution's promotion and tenure process accepts a journal with only an inaugural JIF. Because NEJM Evidence is new and has only that first JIF, some metric-driven promotion committees either discount publications here or require additional explanation.

We have seen career-stage mismatches where an early-career researcher submitted their most important study to NEJM Evidence, which was clinically rigorous and well-placed, but faced a T&P committee that required a listed JIF and did not know how to credit the publication. The fix is simple: confirm your promotion criteria before submitting career-critical work to any journal without a listed JIF.

Papers that belong at JAMA or BMJ but are submitted to NEJM Evidence as a "step down" from NEJM. The logic authors often apply is: "We were rejected by NEJM, so we'll try NEJM Evidence next." That reasoning works when the paper fits NEJM Evidence's scope, clinical trials, evidence synthesis, rigorous clinical epidemiology.

It does not work when the paper is a broader clinical medicine study better suited to JAMA, BMJ, or Annals of Internal Medicine, journals that have longer JIF records and established committee recognition. Using NEJM Evidence as a fallback for any NEJM rejection is a scope mismatch. The paper needs to fit NEJM Evidence's specific focus on clinical trial evidence, not just the NEJM family brand.

Observational studies without rigor appropriate for the NEJM Group standard. NEJM Evidence carries the NEJM Group's editorial expectations for methodological rigor. We see observational studies submitted with the assumption that the lower selectivity compared to NEJM proper means a lower methodological bar. That assumption is wrong. NEJM Group editorial culture demands pre-specified analysis plans, appropriate sensitivity analyses, honest handling of confounding, and complete reporting of null findings.

Observational studies that would pass peer review at a mid-tier clinical journal can face rejection at NEJM Evidence specifically because the methods don't meet the NEJM Group's reporting standards.

If you are deciding whether the short JIF history is worth the tradeoff for a live manuscript, run a NEJM Evidence metric-risk and journal-fit check before you submit.

Good fit:

• Randomized clinical trials with definitive or substantial findings in clinical medicine

• Large systematic reviews or meta-analyses with clear practice implications

• Clinical epidemiology studies with real-world relevance to medical decision-making

• Secondary analyses of major trials that produce practice-relevant insights

Not a good fit:

• Basic science or mechanistic laboratory work

• Small observational studies without meaningful clinical sample sizes

• Case reports or case series

• Narrow disease-specific work better suited to specialist journals

Impact factor is a lagging indicator. It measures citation history, not current quality. NEJM Evidence is new, its editorial standards are high, and its parentage is strong. The formal JIF question still needs a direct Clarivate check before you put a number in a grant, promotion packet, or cover letter.

If you're choosing between NEJM Evidence and a journal that has a longer JIF record but lower editorial standards, the JIF alone isn't a good reason to choose the lower-quality venue. Talk to your department chair or mentors about how your institution actually weighs journal prestige vs. listed metrics.

1. Structure your trial properly. CONSORT compliance, pre-registered protocol, and pre-specified endpoints are expected

1. Clinical relevance is the filter. State the practice implication in the cover letter clearly

1. NEJM Evidence accepts Rapid Review requests. This can be a practical advantage for time-sensitive findings

1. Funder access mandates are supported: NEJM Evidence charges authors no submission or publication fees and supplies an Author Accepted Manuscript PDF for repository deposit

• NEJM submission guide

• NEJM acceptance rate

• Is NEJM a good journal?

• NEJM Evidence journal profile

• What is impact factor?

• JAMA vs NEJM comparison

If the decision is taking a while, the NEJM Evidence Under Review status guide sets out the normal range and the threshold past which a status query is fair.